Analysts Start Mead Johnson Coverage (MJN
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Mead Johnson Nutrition Company (NYSE: MJN) has reached the end of its analyst quiet period where the firms who underwrote the deal can now begin their ratings coverage. This was the Bristol-Myers Squibb Co. (NYSE: BMY) spin off. If you will recall, Citigroup and Morgan Stanley were the joint book-runners on the deal. Banc of America, Credit Suisse, J.P.Morgan, RBC, UBS, and Lazard were the co-managers of the underwriting. These are the calls we have seen far for New analyst coverage initiations:
- ‘Buy’ at Citigroup (joint book-runner)
- ‘Equal Weight’ at Morgan Stanley (joint book-runner)
- ‘Outperform’ at RBC Capital
- ‘Neutral’ at B of A Merrill
- ‘Neutral’ at JPMorgan
- ‘Neutral’ at Credit Suisse
This is still up about 10% since its IPO in early February.
JON C. OGG
March 23, 2009
Contact [email protected] for any questions or corrections.